New biomarkers of bladder cancer in liquid biopsies

Fernandes, F.; Flores, Juan; Horvatovich, Péter; Lodeiro, Carlos; Martínez, J. Larrauri; Santos, Hudson Andrade dos; Calais, F.; Pinheiro, Laura C.

doi:10.1016/s1569-9056(19)31190-x

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NMP22 is a protein marker approved by the Food and Drug Administration (FDA) for urine-based markers to detect BC, which has clinical utility and higher sensitivity in most cases. 33,34 Therefore, NMP22 was chosen for quantitative detection. First, a mouse anti-NuMA primary antibody with a dilution of 1 : 100 was injected into the modied PDMS chip and incubated at 37 °C in a humid atmosphere for 1 h. The channels were rinsed four times with PBS (PH = 7.4) to remove the unbound antibody.…”

Section: 5mentioning

confidence: 99%

Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22

Guan

Chen

et al. 2023

Anal. Methods

View full text Add to dashboard Cite

show abstract

Section: 5mentioning

confidence: 99%

Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22

Guan

Chen

et al. 2023

Anal. Methods

View full text Add to dashboard Cite

show abstract

Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer

Silva Medeiros,

Botelho de Carvalho,

Alves

et al. 2024

Int Urol Nephrol

View full text Add to dashboard Cite

Purpose T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker. Methods Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan–Meier curves were used for data analysis. Results Patients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts. Conclusion This study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.

show abstract

New biomarkers of bladder cancer in liquid biopsies

Cited by 2 publications

References 0 publications

Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22

Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22

Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer

Contact Info

Product

Resources

About